Merck & Co, INC Form 4 insider transactions

David R. Maraldo, EVP & Pres. MMD at Merck & Co., Inc., reported transactions involving restricted stock units and stock options.

Merck & Co., Inc. executive Johannes Jacobus Oosthuizen reported transactions involving restricted stock units and stock options.

Merck & Co., Inc. SVP Fin. - Global Controller Dalton E. Smart III reported transactions involving restricted stock units and stock options.

Merck & Co., Inc. executive Chirfi Guindo has reported transactions involving restricted stock units and stock options.

Dalton E. Smart III, SVP Fin. - Global Controller at Merck & Co., Inc., reported transactions involving common stock and restricted stock units.

David R. Maraldo, EVP & Pres. MMD at Merck & Co., Inc., reported transactions involving common stock and restricted stock units.

EVP Chirfi Guindo exercised restricted stock units and withheld shares for tax obligations in a routine SEC Form 4 filing.

Sanat Chattopadhyay, Executive VP and President of MMD at Merck & Co., reported the vesting and partial sale of restricted stock units.

Richard R. DeLuca, EVP and President of Merck Animal Health, reported the vesting and acquisition of 2,518 shares of common stock.

David Michael Williams, EVP and Chief Info & Digital Officer at Merck & Co., Inc., reported the vesting and partial withholding of restricted stock units.

SVP and Global Controller Dalton E. Smart III exercised restricted stock units and sold shares to cover tax obligations.

Merck & Co. Executive VP Dean Y. Li acquired 4,722 shares through the vesting of restricted stock units and disposed of 2,326 shares to cover tax obligations.

Merck & Co. EVP and General Counsel Jennifer Zachary acquired 2,951 shares via restricted stock unit vesting.

Merck & Co. EVP and Chief HR Officer Betty Larson reported the vesting and settlement of restricted stock units and subsequent tax-related share dispositions.

Merck & Co. EVP and CFO Caroline Litchfield acquired 3,935 shares through the vesting of restricted stock units, with 1,938 shares withheld for tax obligations.

Merck & Co. Chairman and CEO Robert M. Davis acquired 13,300 shares through the vesting of restricted stock units.

Johannes Oosthuizen, EVP of Oncology & International at Merck & Co., reported the vesting and partial sale of restricted stock units.

Merck & Co. Director Christine E. Seidman acquired 67.5451 phantom stock units under a deferred compensation plan, to be settled in cash upon termination of service.

Merck & Co. Director Thomas H. Glocer reported the acquisition of 405.2706 phantom stock units and a direct holding of 5,100 common shares.

Merck & Co. Director Mary Ellen Coe acquired 249.3973 phantom stock units as part of her compensation plan.

Merck's Chief Marketing Officer, Chirfi Guindo, executed a pre-planned sale of 10,000 common shares at an average price of $121.4562.

Merck & Co., Inc.'s Chief Marketing Officer, Chirfi Guindo, sold 10,000 shares of common stock for approximately $1.18 million on February 9, 2026, pursuant to a Rule 10b5-1 plan.

Merck's EVP, General Counsel, Jennifer Zachary, exercised and immediately sold a significant number of stock options, realizing gains.

Merck's EVP, Chief Information & Digital Officer, David Michael Williams, exercised 5,000 stock options and simultaneously sold 5,000 shares of common stock.

Merck's SVP of Finance and Global Controller, Dalton E. Smart III, exercised stock options and subsequently sold a portion of his common stock holdings.

Merck's President of U.S. Market, Johannes Oosthuizen, sold 15,000 shares of common stock for approximately $121.87 per share on February 6, 2026.

Merck & Co.'s EVP & CFO, Caroline Litchfield, executed a pre-planned transaction, exercising stock options and selling the acquired common stock.

Merck & Co. Executive VP Dean Y. Li exercised stock options and subsequently sold 15,087 shares of common stock.

Merck & Co.'s Chief Marketing Officer, Chirfi Guindo, reported the sale of 20,000 shares of common stock for approximately $2.44 million.

Merck & Co. EVP and President of Animal Health, Richard R. DeLuca, reported the sale of 37,685 shares of common stock.